Clin Drug Invest. 2004;24(12):695-717. Finally, subcutaneous insulin aspart every 1 or 2 hours was a well tolerated and cost-effective alternative to a standard intravenous protocol of regular ...

The sharp movement in the early deals was seen after the company announced that it had filed its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drug Controller General of India.

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ...

Drugmaker Wockhardt has approached the Drug Controller General of India (DCGI) seeking approvals for its fast-acting insulin analog, Aspart injection. The company’s Aspart insulin injection ...

Wockhardt has filed for marketing approval of its fast-acting insulin analog, Aspart injection, with the DCGI in India. This move aims to address the growing diabetes epidemic and provide patients ...